Donanemab, a new drug developed by Eli Lilly for the treatment of early forms of Alzheimer's disease, has received a favorable opinion from the EMA committee, recommending its authorization. The drug, which is intended for patients who are non-carriers or heterozygous for apolipoprotein E ε4, has been shown in clinical trials to slow the progression of cognitive impairment. The drug will be available as an infusible solution, and common side effects include amyloid-associated imaging abnormalities and headache. The final authorization decision rests with the European Commission.
Sources
Un nou tratament pentru boala Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Latest News
08:36
Three warehouses of the Russian company Ozon were hit overnight by Ukrainian drones / In Krasnodar, two children died, according to the governor of the region
08:21
Interim Minister of Labor, Dragoș Pîslaru, about the salary law: "Almost 6 billion lei for Education and Health, the maximum that Romania can afford at this moment"
07:57
Who wants the warm pastry? Loredana Groza served the pastries at the SAGA Festival
07:44
Presidential elections in France. Center-left MEP Raphael Glucksmann has announced his candidacy for the 2027 elections.
07:36
Interim Minister of Environment, Diana Buzoianu, about bears that reach localities: "You have no other choice but to have a direct intervention. That is, to have them shot."
See more news